Grupo Ferrer Internacional SA - Company Profile
Powered by 
All the data and insights you need on Grupo Ferrer Internacional SA in one report.
$295
- Save hours of research time and resources with
our up-to-date Grupo Ferrer Internacional SA Strategy Report
- Understand Grupo Ferrer Internacional SA position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Grupo Ferrer Internacional SA (Ferrer) manufactures and markets pharmaceuticals and chemicals products. The company offers its products for various therapeutic areas including cardiovascular, central nervous system, oncology, dermatology, gastrointestinal, phlebology, musculoskeletal system, pain, paediatrics and the respiratory system. It also provides over-the-counter medicines, dermo-cosmetics, food supplements, cough syrups and expectorants, anti-lice and insect repellent products, infant nutrition products, and other skincare products. Ferrer offers its products under Nucleo, Keltican, Nubit, Somazina, Ceraxon, Zynapse, Hidrasec, Tiorfan, Gelocatil, Abfentiq, and Kaptic brand names. The company also offers diagnostics services through its subsidiary Ferrer inCode. The company operates production facilities in Spain and the US. Ferrer is headquartered in Barcelona, Spain.
Headquarters
Spain
Address
Avenida Diagonal, 549, Barcelona, Barcelona , 08029
Website
www.ferrer.com
Telephone
34 936 003700
No of Employees
1,861
Industry
Pharmaceuticals and Healthcare
Grupo Ferrer Internacional SA premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Fine Chemicals | Diagnostics Services | Adasuve |
| Vaccines | Contract Manufacturing | Nucleo |
| Consumer Healthcare | Keltican | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In February, the company acquired rights to develop and commercialize ASN90, an O-GlcNAcase inhibitor, for the treatment of progressive supranuclear palsy (PSP). |
| 2023 | Contracts/Agreements | In February, the company and Asceneuron signed a licensing agreement for O-GlcNAcase inhibitor, ASN90, to treat progressive supranuclear palsy. |
| 2022 | Contracts/Agreements | In February, the company entered into an agreement with United Therapeutics Corporation, to distribute Tyvaso product across the world (except the US, Canada, Japan, China and Israel). |
Competitor Comparison
| Key Parameters | Grupo Ferrer Internacional SA | Novartis AG | AstraZeneca Plc | Grunenthal Pharma SA | neuraxpharm Arzneimittel GmbH |
|---|---|---|---|---|---|
| Headquarters | Spain | Switzerland | United Kingdom | Spain | Germany |
| City | Barcelona | Basel | Cambridge | Madrid | Langenfeld |
| State/Province | Barcelona | - | England | Madrid | Nordrhein-Westfalen |
| No. of Employees | 1,861 | 76,057 | 89,900 | - | - |
| Entity Type | Private | Public | Public | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Mario Rovirosa | Chief Executive Officer | Senior Management | 2018 | - |
| Marta Vela | Chief Operating Officer | Senior Management | - | - |
| Meritxell Casas | Chief Legal Officer | Senior Management | - | - |
| Rodrigo Palma Dos Reis | Chief Medical Officer | Senior Management | 2021 | - |
| David Ferrer | Chief Financial and Corporate Services Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward